PMID- 27042098
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160404
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 9
DP  - 2016
TI  - Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib 
      to thoracic radiotherapy in locally advanced unresectable non-small-cell lung 
      cancer: a Phase II trial.
PG  - 1057-66
LID - 10.2147/OTT.S89755 [doi]
AB  - PURPOSE: Although many studies have confirmed the synergic effects of combining 
      chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and 
      efficacy of erlotinib in combination with RT in locally advanced non-small-cell 
      lung cancer (NSCLC) are limited. The aim of this study was to determine the 
      feasibility, tolerability, and efficacy of the concurrent addition of erlotinib 
      to the standard three-dimensional conformal thoracic RT in patients with 
      unresectable or locally advanced NSCLC who are not candidates for receiving 
      standard CT. PATIENTS AND METHODS: Feasibility and tolerability, assessed by 
      evaluating adverse events (AEs), and effectiveness, by calculating 
      progression-free survival (PFS), overall survival (OS), cancer-specific survival 
      (CSS), and objective response rate (ORR), were analyzed in 30 patients receiving 
      RT alone and 60 receiving RT and erlotinib. RESULTS: Erlotinib with RT showed an 
      extended CSS and a higher rate of complete responses compared with RT alone. No 
      differences between groups were found regarding OS, PFS, and ORR. AEs were 
      significantly higher in the combined treatment, which mainly included cutaneous 
      toxicity, dyspnea, fatigue, hyporexia, diarrhea, and infection. Erlotinib did not 
      increase the toxicity produced by RT. CONCLUSION: The combination of erlotinib 
      with RT produced, in our study, a scarce clinical benefit in the treatment of 
      unresectable or locally advanced NSCLC, limited to complete responses and longer 
      CSS rate compared with RT alone. Increased toxicity events were associated with 
      combined therapy, which mainly included cutaneous toxicity. In our opinion, 
      further studies in molecularly unselected lung cancer patients treated with EGFR 
      TKIs and RT are not indicated. The use of biomarkers for the identification of 
      patients that are most likely to benefit from this treatment is an essential next 
      step in the research of this condition.
FAU - Martinez, Enrique
AU  - Martinez E
AD  - Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
FAU - Martinez, Maite
AU  - Martinez M
AD  - Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
FAU - Rico, Mikel
AU  - Rico M
AD  - Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
FAU - Hernandez, Berta
AU  - Hernandez B
AD  - Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
FAU - Casas, Francesc
AU  - Casas F
AD  - Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain.
FAU - Vinolas, Nuria
AU  - Vinolas N
AD  - Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain.
FAU - Perez-Casas, Ana
AU  - Perez-Casas A
AD  - Department of Radiation Oncology, Jimenez Diaz Foundation, Madrid, Spain.
FAU - Domine, Manuel
AU  - Domine M
AD  - Department of Radiation Oncology, Jimenez Diaz Foundation, Madrid, Spain.
FAU - Minguez, Julian
AU  - Minguez J
AD  - Department of Radiation Oncology, University Hospital of Donostia, San Sebastian, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20160301
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4780183
OTO - NOTNLM
OT  - concurrent
OT  - erlotinib
OT  - non-small-cell lung cancer
OT  - radiotherapy
EDAT- 2016/04/05 06:00
MHDA- 2016/04/05 06:01
PMCR- 2016/03/01
CRDT- 2016/04/05 06:00
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2016/04/05 06:01 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - ott-9-1057 [pii]
AID - 10.2147/OTT.S89755 [doi]
PST - epublish
SO  - Onco Targets Ther. 2016 Mar 1;9:1057-66. doi: 10.2147/OTT.S89755. eCollection 
      2016.